IMMX Immix Price Chart

Immix Biopharma, Inc. (IMMX) is vying for niche dominance through the outpatient blood treatment provided by its NXC-201 drug. Research precision is ensured by strict adherence to temperature controls during the transport of biomaterials. This market valuation chart for the company on the GURU.Markets platform captured a value of 7.84. The business's commercial success depends on overcoming tumor resistance within the expansive and rapidly evolving cell therapy market.

Stock Quotes: Immix Biopharma (IMMX) for 07/04/2022 - 11/14/2026

Summary analytical data breakdowns for immixbio.com (IMMX)

- stock quotes and analyst forecast:

Stock Price Immix|IMMX - Analyst Median Target

- market capitalization data:

Market Value Immix Biopharma|IMMX - Real Price to Acquire Entire Company

- balance sheet equity data:

Net Assets per Single Share Immix Biopharma|IMMX - Company Net Assets|Market Cap to Net Assets Ratio immixbio.com|IMMX - Total Business Assets

- issuer credit burden and liquidity indicators:

- company profitability and valuation multiples indicators:

IMMX - Company Net Income|Expected Profit Immix Biopharma, Inc.|IMMX - Market Cap to Earnings|Forward P/E Multiple Immix Biopharma|IMMX - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Immix Biopharma Inc.|IMMX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Immix Biopharma|IMMX - Earnings per share for the trailing year|Quarterly EPS earnings growth immixbio.com|IMMX - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Immix Biopharma, Inc.

- total revenue and sales volume data:

IMMX - Company Sales|Company Projected Revenue Immix Biopharma Inc.|IMMX - Market Cap to Revenue|Forward Price-to-Revenue Multiple Immix

Summary company analytics:Immix Biopharma, Inc.

Signature product of Immix Biopharma, Inc.

Immix Biopharma, Inc. (IMMX) pipeline diversification in immunotherapy distributes development risks, which directly impacts the market value of its assets. The stock price history captures the current valuation per share, allowing investors to track capital flow and the market's reaction speed to the company's clinical successes to manage their long-term investment strategy.

Competitors of Immix Biopharma, Inc.